13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE 13D Filed 2026-08-21 Event 2026-05-03 SEC 0001725092-26-000015 →

Lin Shao-Lee Cue Biopharma, Inc. CUE

Stake: 6.20% Shares: 467,166 CUSIP: 22978P205 Class: Common Stock, $0.001 par value per share ("Common Stock")

Item 4 — Purpose of Transaction

The Reporting Person intends to review her investment in the Common Stock and the Issuer's securities on a regular basis and, as a result thereof, may, directly or through one or more affiliates, at any time or from time to time determine, either alone or as part of a group, (i) to acquire additional securities of the Issuer, through open market purchases, privately negotiated transactions, or otherwise, (ii) to dispose of all or a portion of the securities of the Issuer beneficially owned by her in the open market, in privately negotiated transactions, or otherwise, or (iii) to take any other available course of action, which could involve one or more of the types of transactions or have one or more of the results specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"). Any such acquisition or disposition or other transaction would be made in compliance with all applicable laws and regulations, and subject to the terms and conditions of any agreements between the Reporting Person and the Issuer. Notwithstanding anything contained herein, the Reporting Person intends to review her investment in the Issuer and the Issuer's performance and market conditions periodically and to take such actions with respect to her investment as she deems appropriate considering the circumstances existing from time to time. Accordingly, the Reporting Person specifically reserves the right to change her intention with respect to any or all such matters described above. In reaching any decision as to her course of action (as well as to the specific elements thereof), the Reporting Person currently expects that she would take into consideration a variety of factors, including, but not limited to, the following: the Issuer's business and prospects; other developments concerning the Issuer and its businesses generally; other business opportunities available to the Issuer; changes in law and government regulations; general economic conditions; tax considerations; other investment opportunities available to the Reporting Person; and prevailing market conditions, including the market price of the securities of Issuer. Other than as described above, the Reporting Person does not have any plan or proposal which relates to or would result in any of the transactions described in clauses (a) through (j) of Item 4 of Schedule 13D, although the Reporting Person reserves the right to do so. As President, CEO and a member of the Board, the Reporting Person regularly explores potential actions and transactions that may be advantageous to the Issuer and/or any of its subsidiaries, including possible mergers, acquisitions, reorganizations or other material changes in the business, corporate structure, the Board, management, dividend policy, governing documents, contractual arrangements, capitalization or securities of the Issuer. In addition, as compensation for her service as an executive officer of the Issuer, the Reporting Person may be granted equity awards or other similar compensation that would result in the Reporting Person beneficially owning additional securities of the Issuer.

Cross-References

Insider Activity (last 365d)
12 transactions
12 buys · 0 sales · 0 awards/exercises
Issuer Cluster
2 13D/G filings on this issuer
1 other filing besides this one
Filer Track Record
1 filings by this filer
0 other filings in the data moat
Short Interest · settle 2026-07-31
DTC 1.89
349,876 shares short · +13.6% vs prior

Form 4 Insider Transactions · last 365d

DateInsiderRoleTypeSharesPriceValue
2026-07-13 Borie Dominique Christian officer Award 31,500
2026-07-13 Borie Dominique Christian officer Award 63,000 $30.92 $1.95M
2026-07-09 Garzone Pamela director Award 21,800
2026-07-09 Camardo Daniel A. director Award 21,800
2026-07-09 Sarraf Pasha director Award 21,800
2026-07-09 Meehan Viola Mong director Award 21,800
2026-07-09 Meluzio Michael Vincent officer Award 40,942
2026-07-09 Meluzio Michael Vincent officer Award 40,942
2026-07-09 Ray Sumita officer Award 54,589
2026-07-09 Ray Sumita officer Award 54,589
2026-07-09 Lin Shao-Lee director, officer Award 327,537
2026-07-09 Lin Shao-Lee director, officer Award 327,537

Other 13D/G Filings on Cue Biopharma, Inc.

FiledFormFilerStakeShares
2020-04-21 SC MARLETT CHRISTOPHER A view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →